The Experts below are selected from a list of 171 Experts worldwide ranked by ideXlab platform
H. N. Madhavan - One of the best experts on this subject based on the ideXlab platform.
-
Efficacy and safety of 1% Rimexolone versus 1% prednisolone acetate in the treatment of anterior uveitis – a randomized triple masked study
International Ophthalmology, 2004Co-Authors: Jyotirmay Biswas, T. M. Ganeshbabu, S. Ramesh Raghavendran, Seemant Raizada, Sandeep V. Mondkar, H. N. MadhavanAbstract:Purpose: To evaluate the efficacy and safety of 1% Rimexolone versus 1% prednisolone acetate ophthalmic suspension in the treatment of anterior uveitis. Methods: A randomised triple masked, parallel comparison of Rimexolone and prednisolone acetate ophthalmic suspensions was carried out on 78 patients with acute, chronic and recurrent anterior uveitis. Treatment regimen included instillation of one or two drops of drug one hourly through the waking hours during the first week, two hourly in the second week, four times a day in the third week, two times a day for the first 4 days and once a day for the 3 days in the last week. The patient was clinically evaluated on the 3–4th, 7–10th, 14th, 21st and 28th days. The patient was also reviewed on the 30th day. Anterior chamber cells and flare reactions were compared for evaluating the efficacy of the drugs. Result: Rimexolone is as effective as prednisolone acetate ophthalmic suspension in the treatment of anterior uveitis. The largest difference found was 0.1 in the flare reaction (statistically insignificant; p =0.3) and 0.2 score units (statistically significant; p =0.01) in the cells. Overall, comparison of the drugs shows no clinical significance in the treatment of anterior uveitis by either drug. Difference in intraocular pressure (IOP) was also statistically insignificant ( p >0.05). However, three patients in the prednisolone acetate group and 1 patient from the Rimexolone group showed a rise in IOP. Conclusion: Rimexolone 1% ophthalmic suspension is as effective as and safer than prednisolone acetate 1% ophthalmic suspension in the treatment of anterior uveitis.
-
Efficacy and safety of 1% Rimexolone versus 1% prednisolone acetate in the treatment of anterior uveitis--a randomized triple masked study.
International ophthalmology, 2004Co-Authors: Jyotirmay Biswas, T. M. Ganeshbabu, Seemant Raizada, Sandeep V. Mondkar, S. Ramesh Raghavendran, H. N. MadhavanAbstract:Purpose: To evaluate the efficacy and safety of 1% Rimexolone versus 1% prednisolone acetate ophthalmic suspension in the treatment of anterior uveitis. Methods: A randomised triple masked, parallel comparison of Rimexolone and prednisolone acetate ophthalmic suspensions was carried out on 78 patients with acute, chronic and recurrent anterior uveitis. Treatment regimen included instillation of one or two drops of drug one hourly through the waking hours during the first week, two hourly in the second week, four times a day in the third week, two times a day for the first 4 days and once a day for the 3 days in the last week. The patient was clinically evaluated on the 3–4th, 7–10th, 14th, 21st and 28th days. The patient was also reviewed on the 30th day. Anterior chamber cells and flare reactions were compared for evaluating the efficacy of the drugs. Result: Rimexolone is as effective as prednisolone acetate ophthalmic suspension in the treatment of anterior uveitis. The largest difference found was 0.1 in the flare reaction (statistically insignificant; p=0.3) and 0.2 score units (statistically significant; p=0.01) in the cells. Overall, comparison of the drugs shows no clinical significance in the treatment of anterior uveitis by either drug. Difference in intraocular pressure (IOP) was also statistically insignificant (p>0.05). However, three patients in the prednisolone acetate group and 1 patient from the Rimexolone group showed a rise in IOP. Conclusion: Rimexolone 1% ophthalmic suspension is as effective as and safer than prednisolone acetate 1% ophthalmic suspension in the treatment of anterior uveitis.
C. Stephen Foster - One of the best experts on this subject based on the ideXlab platform.
-
A pharmacoeconomic analysis of Rimexolone for the treatment of ophthalmic inflammatory conditions.
The American journal of managed care, 1998Co-Authors: Michael T. Halpern, Cynthia S. Palmer, C. Stephen Foster, Ashish Pal, Carmelina BattistaAbstract:Topical steroids are the standard first-line therapy for treating ophthalmic inflammatory conditions. However, potent ophthalmic steroids can lead to an elevation of intraocular pressure (IOP), which can result in greater medical resource utilization and increased costs. We have developed a decision analysis model from a societal perspective to evaluate the costs and consequences of the treatment of ophthalmic inflammatory conditions with two potent topical steroids: prednisolone and Rimexolone. Data for the model are based on information from clinical trials, national data-bases, published literature, and responses by ophthalmologists to a questionnaire on treatment patterns for elevated IOP. Three steroid-responsive conditions are examined separately with the model: uveitis; postoperative inflammation following cataract surgery; and other ophthalmic inflammatory conditions (blepharitis, episcleritis, postoperative refractive surgery, and corneal transplant). The model evaluates patients with acute conditions versus those with chronic conditions and those with mild to moderate elevation of IOP versus those with severe elevation of IOP. Although the unit cost of Rimexolone is higher than that of prednisolone, use of Rimexolone leads to cost savings because the incidence of elevated IOP is decreased. If Rimexolone is used instead of prednisolone for the treatment of ophthalmic inflammatory conditions, the estimated cost saved (at 1995 AWP prices) is approximately $10 million across the entire US population. The savings across the health maintenance organization population on an annualized basis is approximately $3.9 million. Even if Rimexolone were priced higher than current market charges (at 130% to 150% of the AWP of prednisolone), cost savings ranging from the $2.9 million to $720,000 would accrue with use of Rimexolone compared with prednisolone. However if, Rimexolone were priced at 160% of the AWP of prednisolone, its use would incur an additional cost of $300,000. The primary medical resource utilized in treating elevated IOP in ophthalmic inflammatory conditions is physician visits. Medications are responsible for only one-fifth to one-third of the total cost of treating elevated IOP. This analysis indicates that Rimexolone is associated with decreased medical resource utilization and cost savings to the entire healthcare system.
-
Efficacy and Safety of Rimexolone 1 % Ophthalmic Suspension vs 1% Prednisolone Acetate in the Treatment of Uveitis
American journal of ophthalmology, 1996Co-Authors: C. Stephen Foster, George Alter, L. Raymond Debarge, Michael B. Raizman, James L. Crabb, Carmen Santos, Mitchell H. Friedlaender, L. Scott FeilerAbstract:Purpose TWO multicenter studies compared the efficacy and safety of Rimexolone 1% ophthalmic suspension (Vexol 1%, Alcon) and 1% prednisolone acetate (Pred Forte, Allergan). Methods Patients with acute uveitis, recurrent iridocyclitis, or chronic uveitis treatable by topical corticosteroid were enrolled. Treatment regimen was one or two drops every hour during Week 1, every two hours during Week 2, four times a day during Week 3, and once a day for the last three days. Efficacy and safety were determined on Days 3, 4, 7 to 10, 14, 21, and 28. A poststudy evaluation was conducted 36 to 72 hours after treatment was stopped. Results When anterior chamber cell and flare were measured, Rimexolone 1% was found to be as effective as 1% prednisolone. The largest differenee observed between treatments was 0.5 score unit, not clinically significant. There were no statistically significant differences in cell scores in either study (P > .05). No statistically significant differences in flare scores were found except at Day 28 in Study One (P = .04). Also, prednisolone was found to be more likely than Rimexolone to cause a clinically significant increase (10 mm Hg or more) in intraocular pressure (1.7 times more likely in Study One, eight times more likely in Study Two). Conclusions Rimexolone 1% ophthalmic suspension is safe and effective for the treatment of uveitis.
Oren Tomkins-netzer - One of the best experts on this subject based on the ideXlab platform.
-
Outcome and risk of ocular complications of managing children with chronic anterior uveitis with topical Rimexolone 1.
International ophthalmology, 2020Co-Authors: Y.–h. Chen, Raz Gepstein, Lazha Sharief, Hsiao-jung Tseng, Ruoxin Wei, Xiaozhe Zhang, Susan Lightman, Oren Tomkins-netzerAbstract:PURPOSE To investigate the efficacy and safety of 1% Rimexolone ophthalmic suspension in children with chronic anterior uveitis under real-life conditions in a tertiary center. METHODS This is a retrospective longitudinal study. Medical records were analyzed at baseline, 1, 3, 6 and 12 months before and after switching to Rimexolone for best-corrected visual acuity (BCVA), oral steroid use, number of flares, IOP and anti-glaucoma management. RESULTS Twenty-four patients (41 eyes) diagnosed with either anterior uveitis (n = 25, 60.0%) or panuveitis (n = 16, 40%) were enrolled. The mean age was 10.5 years (4-16 years). The number of patients requiring oral prednisolone reduced from 8 patients (32.0%) at baseline to 3 patients (20.0%) at 12 months (P 7.5 mg/day oral prednisolone (OR 4.4, P = 0.033). CONCLUSIONS Rimexolone 1% ophthalmic suspension is an effective and safe topical steroid for pediatric anterior uveitis.
-
Outcome and risk of ocular complications of managing children with chronic anterior uveitis with topical Rimexolone 1%
International Ophthalmology, 2020Co-Authors: Yi-hsing Chen, Raz Gepstein, Lazha Sharief, Hsiao-jung Tseng, Xiaozhe Zhang, Sue Lightman, Oren Tomkins-netzerAbstract:Purpose To investigate the efficacy and safety of 1% Rimexolone ophthalmic suspension in children with chronic anterior uveitis under real-life conditions in a tertiary center. Methods This is a retrospective longitudinal study. Medical records were analyzed at baseline, 1, 3, 6 and 12 months before and after switching to Rimexolone for best-corrected visual acuity (BCVA), oral steroid use, number of flares, IOP and anti-glaucoma management. Results Twenty-four patients (41 eyes) diagnosed with either anterior uveitis ( n = 25, 60.0%) or panuveitis ( n = 16, 40%) were enrolled. The mean age was 10.5 years (4–16 years). The number of patients requiring oral prednisolone reduced from 8 patients (32.0%) at baseline to 3 patients (20.0%) at 12 months ( P
Hasan Hasbi Erbil - One of the best experts on this subject based on the ideXlab platform.
-
Rimexolone 1% versus prednisolone acetate in preventing early postoperative inflammation after cataract surgery
International Ophthalmology, 2008Co-Authors: Sevim Kavuncu, Hasan Horoz, Aylin Ardagil, Hasan Hasbi ErbilAbstract:Purpose : To compare the efficacy and safety of Rimexolone 1% and prednisolone acetate 1% ophthalmic suspensions in controlling intraocular inflammation in the early period after cataract surgery. Methods : Eighty patients undergoing cataract extraction with intraocular lens implantation, either planned extra capsular cataract extraction (PECCE) or phacoemulsification surgery, were evaluated in a prospective, randomized, observer-masked, clinical trial in which efficacy in controlling early postoperative inflammation and safety of prednisolone acetate 1% one eye drop every 4 h ( n = 36 eyes) was compared with that of Rimexolone 1% one eye drop every 4 h ( n = 44 eyes) in an eighteen day course. Efficacy was assessed from changes of the anterior chamber cell count, flare, conjunctival hyperemia, and ciliary congestion by means of slit lamp biomicroscopy on days 1, 3, 8, 15, and 18. Intraocular pressure (IOP) and possible side effects were also recorded on each visit. Results : Anterior chamber cell count and flare showed no difference in the two groups at any visits. The Rimexolone group was associated with significantly higher score for conjunctival hyperemia on days one and three ( P
-
Rimexolone 1% versus prednisolone acetate in preventing early postoperative inflammation after cataract surgery
International ophthalmology, 2007Co-Authors: Sevim Kavuncu, Hasan Horoz, Aylin Ardagil, Hasan Hasbi ErbilAbstract:Purpose: To compare the efficacy and safety of Rimexolone 1% and prednisolone acetate 1% ophthalmic suspensions in controlling intraocular inflammation in the early period after cataract surgery. Methods: Eighty patients undergoing cataract extraction with intraocular lens implantation, either planned extra capsular cataract extraction (PECCE) or phacoemulsification surgery, were evaluated in a prospective, randomized, observer-masked, clinical trial in which efficacy in controlling early postoperative inflammation and safety of prednisolone acetate 1% one eye drop every 4 h (n = 36 eyes) was compared with that of Rimexolone 1% one eye drop every 4 h (n = 44 eyes) in an eighteen day course. Efficacy was assessed from changes of the anterior chamber cell count, flare, conjunctival hyperemia, and ciliary congestion by means of slit lamp biomicroscopy on days 1, 3, 8, 15, and 18. Intraocular pressure (IOP) and possible side effects were also recorded on each visit. Results: Anterior chamber cell count and flare showed no difference in the two groups at any visits. The Rimexolone group was associated with significantly higher score for conjunctival hyperemia on days one and three (P < 0.05) and the prednisolone acetate group was associated with a significantly higher score for corneal edema on day 8 (P < 0,05). However, there were no between group differences in IOP. Conclusions: Rimexolone 1% ophthalmic suspension was as effective and safe as prednisolone acetate 1% ophthalmic suspension in controlling inflammation in the early period after cataract surgery.
Scott L Feiler - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of Rimexolone 1 ophthalmic suspension vs 1 prednisolone acetate in the treatment of uveitis
American Journal of Ophthalmology, 1996Co-Authors: Stephen C Foster, George Alter, Michael B. Raizman, James L. Crabb, Carmen Santos, Mitchell H. Friedlaender, Raymond L Debarge, Scott L FeilerAbstract:Purpose TWO multicenter studies compared the efficacy and safety of Rimexolone 1% ophthalmic suspension (Vexol 1%, Alcon) and 1% prednisolone acetate (Pred Forte, Allergan). Methods Patients with acute uveitis, recurrent iridocyclitis, or chronic uveitis treatable by topical corticosteroid were enrolled. Treatment regimen was one or two drops every hour during Week 1, every two hours during Week 2, four times a day during Week 3, and once a day for the last three days. Efficacy and safety were determined on Days 3, 4, 7 to 10, 14, 21, and 28. A poststudy evaluation was conducted 36 to 72 hours after treatment was stopped. Results When anterior chamber cell and flare were measured, Rimexolone 1% was found to be as effective as 1% prednisolone. The largest differenee observed between treatments was 0.5 score unit, not clinically significant. There were no statistically significant differences in cell scores in either study (P > .05). No statistically significant differences in flare scores were found except at Day 28 in Study One (P = .04). Also, prednisolone was found to be more likely than Rimexolone to cause a clinically significant increase (10 mm Hg or more) in intraocular pressure (1.7 times more likely in Study One, eight times more likely in Study Two). Conclusions Rimexolone 1% ophthalmic suspension is safe and effective for the treatment of uveitis.
